Chronic Rhinosinusitis Trial, Not Yet Recruiting NCT07049978 Sponsor: Medical University of Vienna Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Not Yet Recruiting

NCT07049978
Not Yet Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You took part in an earlier related study (reference EK 1044/2020) and have continued taking Dupilumab without stopping since then (this will be based on what you report yourself, as there is no lab test to check this).
  • You have signed and dated a consent form agreeing to take part.
  • You are currently being treated with Dupilumab.

Who may not be able to join:

  • You are pregnant (checked using a urine pregnancy test).
  • You have significantly abnormal blood test results or an active infection such as tuberculosis, HIV, or hepatitis A, B, or C.
  • You have a history of cancer or a condition that weakens the immune system.
  • You have chronic obstructive pulmonary disease (COPD) or other conditions that cause blocked or narrowed airways in the lungs (confirm with trial site).
  • You have needed steroid tablets or injections (systemic corticosteroids) in the month before your screening appointment.
  • You have a condition called eosinophilic pneumonia or Churg-Strauss Syndrome (a rare inflammatory condition affecting blood vessels) (confirm with trial site).
  • You have previously had a severe allergic reaction (anaphylaxis) or have any reason you should not take aspirin (ASA), as listed in the official medication guidance.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sven Schneider Dr. med. univ., MD, Senior doctor and Department of Otorhinolaryngology at Medical University of Vienna

Phone: 014040033480

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
30 June 2026

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Change in ASA tolerance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov